COX-2 inhibitors: chemoprevention of head and neck cancer

Autores/as

  • Mubeen K.
  • Vijayalaxmi K. R.
  • Abhishek Ranjan Pati

DOI:

https://doi.org/10.7213/aor.v7i1.23151

Palabras clave:

Cycloxygenase, Prostaglandins, Oncogenesis

Resumen


Objective: In addition to the well-established pathophysiological role that COX-2 plays in inflammation, recent evidence implies that this isoform may also be involved in multiple biologic events throughout the tumorigenic process. Many epidemiological studies demonstrate that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of a wide range of tumors. Further, COX-2 is chronically over expressed in many premalignant, malignant, and metastatic human cancers, and levels of over expression have been shown to significantly correlate to invasiveness, prognosis, and survival in some cancers. Conclusions: This article presents a broad overview of the growing evidence that COX-2 plays a pivotal role throughout oncogenesis and summarizes the rationale to explore the use of COX-2 inhibitors for the prevention or treatment of cancer as a single agent or in combination with current anticancer modalities. Epidemiological data and preclinical studies have generated compelling interest in the potential use of COX-2 inhibitors in chemoprevention and chemotherapy of human tumours.

Descargas

Los datos de descargas todavía no están disponibles.

Publicado

2011-11-28

Cómo citar

K., M., R., V. K., & Pati, A. R. (2011). COX-2 inhibitors: chemoprevention of head and neck cancer. Archives of Oral Research, 7(1). https://doi.org/10.7213/aor.v7i1.23151

Número

Sección

Revisões